US EditionBreak it Down: LTR Pharma develops new nasal spray for OMD's
Summary by Stockhead
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Break it Down: LTR Pharma develops new nasal spray for OMD's
Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, host Tylah Tully looks at news from LTR Pharma (ASX:LTP) who have signed a collaborative agreement with Strategic Drug Solutions to develop a novel-treatment for oesophageal motility disorders. Using its patented nasal spray technology to treat erectile dysfunction, LTR has created OROFLOW, a treatment designed to enter the bloodstream quickly…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
